Comparing the Efficacy of Concomitant Therapy With the Standard Triple Regimen as First Line Therapy of Helicobactor Pylori Eradication

Abstract

Objective: To compare the effectiveness of Concomitant therapy with standard triple regimen in H.pylori Eradication.
 Methods: It was a randomised control trial at OPD of Department of Gastroenterology, Jinnah Hospital Lahore and involved 170 patients, who fullfilled the selection criteria of study were enrolled in the study from OPD of Department of Gastroenterology, Jinnah Hospital Lahore. 85 cases were given Concomitant therapy (Group-A) and 85 cases were given Standard triple regimen (Group-B). Informed consent was obtained. Demographic information (name, age, and sex) were taken. The mean age was 40.43 ± 17.01 years in the Concomitant therapy group and 42.99 ± 12.98 years in the Standard triple regimen group. In group A, 62% cases had ages less than 45 years, and 37.6% of cases had age 45 years or above. In group B, 68.2% cases had an age less than 45 years and 31.8% of cases had an age of 45 years and above. In group A, 50.6% cases were male and 49.4% cases were female. In group B, 72.9% cases were male and 27.1% cases were female. In group A, 58.8%, 22.4%, and 18.8% of cases had low, middle, and high socioeconomic status respectively. In group B, 57.6%, 29.4 and 13% of cases had low, middle, and high socioeconomic status respectively.
 In the Concomiant therapy group, eradication was achieved in 93.8%. In conventional triple regimen, eradication was achieved in 61.4% cases (p-value<0.001).
 Conclusions: Eradication achievement was significantly more common with Concomitant therapy as compared to the conventional triple regimen. Concomitant therapy was much effective than the Standard triple regimen in all age groups, both genders, and all socioeconomic groups.